Related Experiment Video
Updated: Jan 20, 2026

Plaquing of Herpes Simplex Viruses
Published on: November 5, 2021
Which patients should receive the herpes zoster vaccine?
Mandy D Short1, Christina Fergus
1Mandy D. Short and Christina Fergus are pharmacists at Blue Cross Blue Shield of Arizona. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Abstract:
The recombinant adjuvanted zoster vaccine (RZV, trade name Shingrix) is preferentially recommended by the Advisory Committee on Immunization Practices to prevent herpes zoster and related complications in immunocompetent adults age 50 years and older. This article reviews efficacy and safety of the vaccine, its use in special populations, and how to prevent administration errors to answer the question "Which patients should receive the herpes zoster vaccine?"
Related Concept Videos
04:41Plaquing of Herpes Simplex Viruses
Vaccinations
06:14Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Receiver Operating Characteristic Plot
06:17Expression and Purification of Virus-like Particles for Vaccination
09:14Surface Electromyographic Biofeedback as a Rehabilitation Tool for Patients with Global Brachial Plexus Injury Receiving Bionic Reconstruction
